SAN DIEGO, June 22, 2020 /PRNewswire/ -- Aethlon
Medical, Inc. (Nasdaq: AEMD), a therapeutic medical device and
technology company focused on unmet needs in viral diseases,
oncology and inflammation, today released positive ex vivo
data demonstrating the ability of a laboratory version of the
Company's Hemopurifier® to capture tumor-derived exosomes in
several forms of cancer. The data were presented in e-poster format
by Dr. Annette Marleau, the
Company's Senior Director of Research, at the American Association
for Cancer Research (AACR) Virtual Annual Meeting II, on
June 22, 2020.
Exosomes are subcellular particles that are shed from both
normal and malignant cells and have been shown to mediate multiple
mechanisms of tumor growth and spread. The e-poster, titled,
"Targeting Tumor-Derived Exosomes using a Lectin Affinity
Hemofiltration Device", highlights data from ex vivo studies
which demonstrate that a laboratory version of the Hemopurifier
effectively captures and removes substantial quantities of exosomes
from fluid samples that are circulated through the device. The data
show that the Hemopurifier can clear exosomes that originate from
plasma from patients with diverse cancers, including head and neck
cancer, melanoma, ovarian cancer, esophageal cancer and breast
cancer. The e-poster is available online at
https://www.abstractsonline.com/pp8/#!/9045/presentation/7490.
"Despite abundant research on tumor-derived exosomes and their
role in cancer growth and immunosuppression, a clinical strategy
for influencing exosomes in oncology has been unavailable,"
said Timothy C. Rodell, M.D., Chief Executive Officer of
Aethlon. "The ability to effectively target and capture exosomes
that exhibit signatures of malignancy and immunosuppression offers
a potentially powerful therapeutic strategy for cancer. By reducing
the presence of tumor-derived exosomes in the circulation of
cancer patients, we believe the Hemopurifier may have the potential
to improve the benefits of existing cancer treatment regimens and
emerging immuno-oncology drugs. Our recently announced Early
Feasibility Study in patients with head and neck cancer being
treated with pembrolizumab (KeytrudaÒ) may provide human clinical
data to complement these in vitro studies."
About Aethlon Medical, Inc. and the Hemopurifier®
Aethlon Medical, Inc. is focused on addressing unmet needs in
global health. The Aethlon Hemopurifier is a clinical-stage device
designed to combat cancer and life-threatening viral
infections.
In preclinical studies in cancer, the Hemopurifier depletes the
presence of circulating tumor-derived exosomes that are believed to
promote immune suppression. These tumor derived exosomes also
appear to seed the spread of metastases and therefore may inhibit
the benefit of leading cancer therapies. The Hemopurifier® is an
FDA designated "Breakthrough Device" related to the treatment of
individuals with advanced or metastatic cancer who are either
unresponsive to or intolerant of standard of care therapy, and with
cancer types in which exosomes have been shown to participate in
the development or severity of the disease cancer. The Hemopurifier
also is an FDA designated "Breakthrough Device" related to
life-threatening viruses that are not addressed with approved
therapies.
Aethlon also owns 80% of Exosome Sciences, Inc., which is
focused on the discovery of exosomal biomarkers to diagnose and
monitor cancer and neurological disease progression. Additional
information can be found online at www.AethlonMedical.com and
www.ExosomeSciences.com.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934 that involve
risks and uncertainties. Statements containing words such as "may,"
"believe," "anticipate," "expect," "intend," "plan," "project,"
"will," "projections," "estimate," "potentially," "appear" or
similar expressions constitute forward-looking statements. Such
forward-looking statements are subject to significant risks and
uncertainties and actual results may differ materially from the
results anticipated in the forward-looking statements. Factors that
may contribute to such differences include, without limitation,
Aethlon Medical, Inc.'s (the Company) ability to successfully
complete the Early Feasibility Study, Aethlon's ability to
demonstrate that the removal of exosomes with the Hemopurifier will
result in better outcomes for the treatment of cancer, and
Aethlon's ability to successfully develop and commercialize the
Hemopurifier, its ability to raise additional funds and other
risks. The foregoing list of risks and uncertainties is
illustrative, but is not exhaustive. Additional factors that could
cause results to differ materially from those anticipated in
forward-looking statements can be found under the caption "Risk
Factors" in the Company's Annual Report on Form 10-K for the year
ended March 31, 2019, and in the
Company's other filings with the Securities and Exchange
Commission, including its quarterly Reports on Form 10-Q. Except as
may be required by law, the Company does not intend, nor does it
undertake any duty, to update this information to reflect future
events or circumstances.
Company Contact:
Jim
Frakes
Chief Financial Officer
Aethlon Medical, Inc.
858-459-7800 x3300
Jfrakes@aethlonmedical.com
Media Contact:
Tony
Russo, Ph.D.
Russo Partners, LLC
tony.russo@russopartnersllc.com
212-845-4251
Investor Contact:
Susan
Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com
212-966-3650
View original
content:http://www.prnewswire.com/news-releases/aethlon-medical-presents-hemopurifier-data-at-the-american-association-for-cancer-research-2020-annual-meeting-301080690.html
SOURCE Aethlon Medical, Inc.